Koo2021
2021-06-24
$Orphazyme A/S(ORPH)$
所以暴跌是高盛在减持?
Major shareholder announcement
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":121297922,"tweetId":"121297922","gmtCreate":1624464552766,"gmtModify":1624499397299,"author":{"id":3582108804960981,"authorId":3582108804960981,"authorIdStr":"3582108804960981","name":"Koo2021","avatar":"https://static.tigerbbs.com/960ed65cb0657a2967eb341ca7c010cc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>所以暴跌是高盛在减持?</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>所以暴跌是高盛在减持?</p></body></html>","text":"$Orphazyme A/S(ORPH)$所以暴跌是高盛在减持?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/121297922","repostId":2145096234,"repostType":2,"repost":{"id":"2145096234","pubTimestamp":1624441380,"share":"https://www.laohu8.com/m/news/2145096234?lang=&edition=full","pubTime":"2021-06-23 17:43","market":"us","language":"en","title":"Major shareholder announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2145096234","media":"GlobeNewswire","summary":"Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355\nCopenhagen, De","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a><br/>Company announcement</strong> <br/>No. 18/2021<br/>Company Registration No. 32266355</p>\n<p><strong>Copenhagen, Denmark, </strong><strong>June</strong> <strong>2</strong><strong>3</strong><strong>, </strong><strong>2021</strong> – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notifications pursuant to Section 38 of the Danish Capital Markets Act from The <a href=\"https://laohu8.com/S/GSJ.CL\">Goldman Sachs Group, Inc.</a>, that as of June 16, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments increased to 5.58% of the share capital and voting rights in the Company, and as of June 17, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments has been reduced to less than 5% of the shares and voting rights in the Company.</p>\n<p><strong>For additional information, please contact</strong></p>\n<p><strong>Orphazyme A/S</strong></p>\n<p>Anders Vadsholt, CFO +45 28 98 90 55</p>\n<p><strong><strong>About Orphazyme A/S<br/></strong></strong>Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases. The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA.CO).</p>\n<p> <strong>Attachment</strong> </p>\n<ul>\n<li> 18-2021 Major shareholder announcement </li>\n</ul>\n<br/>\n<img height=\"1\" src=\"https://ml-eu.globenewswire.com/release/track/ab97a514-8cb0-4895-b1a1-25174d411524\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Major shareholder announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMajor shareholder announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 17:43 GMT+8 <a href=https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355\nCopenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage ...</p>\n\n<a href=\"https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/2iUcqQwbjj9QOPtHjGOkfA--~B/aD03NTt3PTM0NTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/uu/api/res/1.2/vfvfNeFz16X8Xf.Xnz2DtQ--~B/aD03NTt3PTM0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dca640c6ad18044be86fa831a7752766","relate_stocks":{"GS":"高盛"},"source_url":"https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145096234","content_text":"Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355\nCopenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notifications pursuant to Section 38 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc., that as of June 16, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments increased to 5.58% of the share capital and voting rights in the Company, and as of June 17, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments has been reduced to less than 5% of the shares and voting rights in the Company.\nFor additional information, please contact\nOrphazyme A/S\nAnders Vadsholt, CFO +45 28 98 90 55\nAbout Orphazyme A/SOrphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases. The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA.CO).\n Attachment \n\n 18-2021 Major shareholder announcement","news_type":1},"isVote":1,"tweetType":1,"viewCount":1422,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ORPH"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/121297922"}
精彩评论